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Risks and Benefits of Using a Commercially
Available Ventricular Assist Device for Failing
Fontan Cavopulmonary Support: A Modeling
Investigation
Masoud Farahmand, Minoo N. Kavarana, Ethan O. Kung*1
Abstract— Fontan patients often develop circulatory failure and are
in desperate need of a therapeutic solution. A blood pump surgically
placed in the cavopulmonary pathway can substitute the function of
the absent sub-pulmonary ventricle by generating a mild pressure
boost. However, there is currently no commercially available device
designed for the cavopulmonary application; and the risks and
benefits of implanting a ventricular assist device (VAD) originally
designed for the left ventricular application on the right circulation
of failing Fontan patients is not yet clear. Moreover, further
research is needed to compare the hemodynamics between the two
clinically-considered surgical configurations for cavopulmonary
assist, with Full and IVC Support corresponding to the entire
venous return or only the inferior venous return, respectively, being
routed through the VAD. In this study, we used a numerical model
of the failing Fontan physiology to evaluate the Fontan
hemodynamic response to a left VAD during the IVC and Full
support scenarios. We observed that during Full support the VAD
improved the cardiac output while maintaining blood pressures
within safe ranges, and lowered the IVC pressure to <15mmHg;
however, we found a potential risk of lung damage at higher pump
speeds due to the excessive pulmonary pressure elevation. IVC
support, on the other hand, did not benefit the hemodynamics in the
patient cases simulated, resulting in the superior vena cava pressure
increasing to an unsafe level of >20 mmHg. The findings in this study
may be helpful to surgeons for recognizing the risks of a
cavopulmonary VAD and developing coherent clinical strategies for
the implementation of cavopulmonary support.
Index Terms— Ventricular assist device (VAD), lumped
parameter network model, congenital heart disease, Fontan
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I. INTRODUCTION

ver the past 50 years, Fontan operation has been the most
common palliative care for patients with single ventricle
defect. Currently 50,000-70,000 patients exist worldwide
that have been able to survive into adulthood because of the
Fontan operation [1]. Ohuchi et al. [2] studied the
hemodynamics in nearly 500 Fontan patients, separating them
into early (0.5-5 years postoperative) and late (≥15 years
postoperative) groups; the age range for the early and late
groups were 9±6 years and 23±7 years, respectively; they
showed that the long-term outcomes of the Fontan operation is
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associated with high mortality. A significant number of these
patients will eventually develop circulatory failure as a result of
the poor hemodynamics following the Fontan procedure [3],
[4]. Based on a 10 year follow up study, 1 out of 4 children after
the Fontan operation are not expected to survive [4]. Previous
clinical measurements [4]–[6] have recorded pulmonary
arterial hypotension and high caval pressure (also known as the
“Fontan paradox”) in single ventricle patients after the Fontan
procedure. Chronic high caval pressure is found to be the main
determinant of many Fontan-related diseases and circulatory
failure [7]. Failing stage in a Fontan circulation manifests itself
in a cascade of the pathological consequences such as proteinlosing enteropathy, hepatic failure, and gut dysfunction [8].
Most failing Fontan patients are unable to receive heart
transplantation either because they are poor candidates as a
result of the several previous surgeries and multiple organ
dysfunctions, or because of the unavailability of matching
organ donors; these patients are in need of an immediate
therapeutic solution. The use of ventricular assist device (VAD)
for systemic circulatory support (left support) [9], [10] or
cavopulmonary support (right support) [11]–[13] has been
proposed for treatment of Fontan failure. This study focuses on
the cavopulmonary support scenario where a mechanical assist
device propels the venous return forward into the lungs as an
attempt to reverse the Fontan paradox. Conceptually, a pump
properly implemented in the cavopulmonary pathway could
generate a slight pressure boost that benefits the hemodynamics
by lowering the caval pressure and augmenting the cardiac
output. Earlier studies either have suggested implementing the
cavopulmonary device to directly pump the inferior vena cava
(IVC) flow to the pulmonary artery (“IVC assisted
configuration”) [13]–[16] or proposed the “Fully assisted
configuration” to pump the entire venous return to the
pulmonary artery [11], [17] (Fig. 1). Previously, Molfetta et al.
[16] showed that an ideal cavopulmonary pump could promote
the cardiac output by 34% during IVC support. To our
knowledge, there has been no study that directly assesses how
the hemodynamics compare between these two surgical
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configurations for the installation of the cavopulmonary assist
device.
A concerted work is in progress to develop a cavopulmonary
assist device as a bridge to cardiac transplantation or for longterm support. Researchers have suggested several prototypes
for powering the Fontan circulation [14], [18]–[21]. While
these prototypes are designed to be compatible with a lowpressure operating environment, they are not commercially
available and thus not employed in the clinical management of
single ventricle patients. As such, a relevant clinical question is
whether an existing VAD originally designed for the left side
application can be used as right-side support in a failing Fontan
patient.
Therefore, the objectives of this study are 1) to identify the
possible risks and benefits of the off-label use of the Jarvik 2000
(or another left VAD with similar mechanical performance) for
IVC and Full support in adult failing Fontan patients, and 2) to
assess how the hemodynamics compare between the IVC and
Fully assisted surgical configurations for installation of the
cavopulmonary assist device. We hypothesized that it is
possible to use a left VAD for the cavopulmonary application
and to palliate the failing Fontan condition albeit with potential
risks. To test this hypothesis, we first performed a sensitivity
analysis on a lumped parameter network (LPN) model of the
healthy adult Fontan physiology to attain a quantitative
understanding how different factors affect the Fontan
circulation; next we constructed a failing Fontan circulation
model and simulated the IVC and Fully assisted surgical
configurations to determine hemodynamic aberrations of each
configuration at different pump speeds.
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Fig. 1. Schematic representation of the surgical configurations for the
cavopulmonary assist installation. (A) Fully assisted configuration (Full
support) and (B) IVC assisted configuration (IVC support). LPA: Left
pulmonary artery, RPA: Right pulmonary artery SVC: Superior vena
cava, IVC: Inferior vena cava
II.

MATERIAL AND METHODS

A. Physiology model of the healthy Fontan circulation
(baseline)
A closed-loop LPN was employed to model the Fontan
physiology (Fig. 2). A full description of the modelling protocol
has been described in our previous work [22]. Briefly, the LPN
can adjust model parameters such as cardiac function, vascular

resistances, vascular compliances, and respiratory parameters
to simulate the hemodynamics of a Fontan patient. The
transmyocardial pressure (Psv) generated by the single ventricle
drives the flow in the circuit and is defined to be correlated with
the ventricular elastance and volume. The ventricular timedependent elastance “E(t)” is defined as a function representing
ventricular filling and contraction.
𝑃
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t is the time point in the cardiac cycle. The systolic period is
given by tsvs, where Vsv0 and Vsv are the ventricular reference
volume and ventricular volume, respectively. En is the
normalized elastance function. Emax is related to the contractility
and ventricular ejection fraction. Eoffset reflects ventricular
filling. The ventricular compliance is correlated with
ventricular filling and thus Eoffset is also considered as a measure
of the ventricular compliance.
In this study, we tuned the LPN models according to [22] to
represent two healthy adult example Fontan patients with a
small and large body surface area (BSA) under resting
condition. The small patient has weight=50kg and
height=150cm and the large patient has weight=75kg and
height=180cm.
B. Sensitivity analysis
Most of the single ventricle patients following the Fontan
operation display signs of ventricular diastolic dysfunction and
elevated pulmonary vascular resistance [23]–[25]. To
determine how ventricular diastolic dysfunction and pulmonary
vascular resistance affect hemodynamic parameters such as
cardiac output, atrial pressure, and IVC pressure in a failing
Fontan circulation, we performed a sensitivity analysis using
LPN simulations where in each example patient we decreased
the ventricular compliance by an amount from 0 to 75% and
increased the pulmonary vascular resistance by an amount from
0 to 100% of their baseline values with a step change of 25%.
We maintained the ventricular contractility at its baseline value
because previous studies have shown that ejection fraction is
mostly preserved in the majority of failing and healthy Fontan
patients [24], [26], [27].
C. Physiology model of the failing Fontan circulation
A failing circulation is characterized by high pulmonary
vascular resistance and low cardiac output [7]. Increased
pulmonary vascular resistance is partly attributable to low
pulmonary pressure and attenuated pulmonary vascular
pulsatility in Fontan patients [25]. Clinical reports show that on
average in a failing Fontan circulation, pulmonary vascular
resistance is elevated by 68% [7] and cardiac output is reduced
by 40% [7], [28] compared to the healthy Fontan circulation.
Moreover, Hebson et al. [5] reported that adult failing
Fontan patients had lower systemic vascular resistance in
comparison with asymptotic Fontan patients, possibly due to
the autonomic control maintaining the total vascular resistance.
A previous report showed that 73% of the Fontan patients also
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suffer from a decrease in ventricular compliance (resulting in
ventricular diastolic dysfunction) that initiates early after the
Fontan procedure possibly as a result of preload depletion [24].
To simulate the failing Fontan circulation based on these
clinical findings, we first increased the pulmonary vascular
resistance by 68% from the baseline. Then, we reduced the
systemic vascular resistance to compensate for the elevated
pulmonary vascular resistance such that the total vascular
resistance is maintained. Finally, we decreased the ventricular
compliance from the baseline to obtain a 40% reduction in the
cardiac output emulating ventricular diastolic dysfunction.
D. Model of cavopulmonary support
Using the failing Fontan LPN, we modelled the IVC and
Fully assisted cavopulmonary support configurations as shown
in Fig. 2. Two thirds of the left VADs implanted in patients in
the USA are axial-flow VADs [29], many with similar
hydraulic characteristics curves as the Jarvik 2000 (Jarvik
Heart, Inc., New York, NY, USA). The performance range of
the Jarvik 2000 can encompass the characteristic curves of
several commonly used VADs operating at their lowest rotor
speeds (Fig. 3A) [30], [31]. Therefore, we modelled the Jarvik
2000 as a representative VAD in this study.
The off-the-shelf operating range of the Jarvik pump is 800012000rpm. We modified the off-the-shelf controller to achieve
lower pump speeds down to 4400rpm, then performed a series
of physical flow experiments to characterize the blood pump
(Fig. 3B). The details of the flow experiments are included in
the supplementary materials. The pump model is presented in
the form of a quadratic equation [32], [33].
𝐵𝑄 𝐶 (3)
∆𝑃 𝐴 𝑄
Where ∆𝑃 is the pressure head across the pump and Q is the
flowrate through the pump ranging from 0 to 6 L.min-1. A, B,
and C are constants dependent on the pump speed (Table. 1).
III.

LVAD

Fig. 2. LPN model of the Fontan circulation coupled with the VAD
describing either the (A) Full Support or (B) IVC Support scenario.
Pressure points (Psub) are labelled on the diagram. Lsub and Rsub are
inductor and resistor components, respectively. [22]
TABLE 1
Coefficients for the Jarvik 2000 blood pump performance
characteristic model at different rotor speeds.
Rotor speed
Coefficients
A
B
C
(rpm)
4400
-0.002356
-0.1267
20.55
5500
-0.003486
-0.0711
30.83
7000
0.01323
-0.8355
56.91
8500
0.0106
-0.854
79.86
9500
0.02024
-1.511
107.2

RESULTS

A. Sensitivity analysis
We quantified the sensitivity of the Fontan hemodynamics to
variations in the pulmonary vascular resistance and ventricular
compliance (Fig. 4). Both example patients we simulated had a

A

similar response to the sensitivity analysis. While the cardiac
output and atrial pressure were affected by both pulmonary
vascular resistance and ventricular compliance, they were more

B
HeartWare CircuLite [30]
HeartWare HVAD [31]
Terumo DuraHeart [31]
Jarvik 2000 (4400rpm)
Jarvik 2000 (12000rpm)

-1

Flow (L.min )

125

Pressure head (mmHg)

Pressure head (mmHg)

HeartMate II axial CF [31]

4400 rpm
5500 rpm
7000 rpm
8500 rpm
9500 rpm
Off-the-shelf
operating range

100
75
50
25
0
0.0

1.5

3.0

4.5

6.0

-1

Flow (L.min )

Fig. 3. Blood pump characteristic curves. (A) Comparison of head curves of several commonly used left VADs operating at their lowest rotor speeds vs the
operating range of the Jarvik 2000, and (B) Performance curves of the Jarvik 2000 blood pump at different rotor speeds.

Pivc response (%)
25% Compliance decrement
50% Compliance decrement
75% Compliance decrement
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1.5
1.0
0.5
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Fig. 4. Hemodynamic response of the large simulated patient to the
variations in the pulmonary vascular resistance (PVR) and ventricular
compliance. CO: Cardiac output, Pivc: IVC pressure and Psa: Atrial
pressure.

sensitive to the ventricular compliance. For every 25%
decrement in the compliance, the cardiac output decreased by
~11% and atrial pressure increased by ~24%. For every 25%
increment in the pulmonary vascular resistance, the cardiac
output decreased by ~3%, and atrial pressure decreased by
<2.5%. Moreover, the slope of the lines at different levels of
ventricular compliance indicated that the atrial pressure became
slightly more sensitive to the pulmonary vascular resistance at
lower ventricular compliances. The IVC pressure is sensitive
to changes in both the pulmonary vascular resistance and the
ventricular compliance.
B. Failing Fontan physiology
In our simulations, the hemodynamic parameters of a failing
circulation were significantly different from those of the
healthy Fontan patients (Table. 2 and Fig. 5). Compared to the
baseline, the arterial pressure in the failing circulation was
significantly lower (~30%); the clinical data reported by
Cavalcanti et al. [28] and Egbe et al. [6] similarly showed a 23%
decrease in arterial pressure. The simulations indicated that the
IVC pressure elevated on average by ~50% (6.5mmHg) in the
failing Fontan patients comparing to the baseline, also
consistent with previous reports [5], [6], [28]. The atrial
pressure substantially increased in the failing Fontan models by
an average of ~81 %.
TABLE 2
Mean values of the hemodynamic parameters from simulations of the two
example Fontan patients at baseline and during Fontan failure.
Parameters
Baseline / Failing
Small patient
Large patient
Height (cm)
150
180
Weight (kg)
50
75
1.44
1.94
BSA (m2)
-1
3.56 / 2.14
4.71 / 2.86
Cardiac output (L.min )
Arterial pressure (mmHg)
89.44 / 63.10
87.64 / 61.69
Atrial pressure (mmHg)
8.02 / 14.62
7.46 / 13.45
Pulmonary pressure (mmHg)
12.29 / 18.90
11.66 / 17.88
IVC pressure (mmHg)
12.29 / 18.90
11.66 / 17.88
IVC: Inferior vena cava

0.0

CO

Pa

Pivc

Psa

Ppul

Fig. 5. Failing Fontan hemodynamics in comparison with the baseline.
The averaged hemodynamic data of two example failing Fontan patients
were normalized with respect to the baseline. Cardiac output (CO), arterial
pressure (Pa), IVC pressure (Pivc), pulmonary pressure (Ppul) and atrial
pressure (Psa) are presented.

C. Cavopulmonary support for the failing Fontan circulation
(Fig. 6)
1) Fully assisted configuration
The presence of the VAD increased the cardiac output and
favourably decreased the IVC pressure across all pump speeds
for the small patient but only above 5000rpm for the large
patient. For the large patient with rpm <5000, the cardiac output
and the IVC pressure deteriorated and changed by ~ -7.5% and
~+5.6%, respectively.
For both patients, the cavopulmonary VAD generally
resulted in the reduction of the superior vena cava (SVC)
pressure. For every 1000rpm increase in the pump speed, the
IVC pressure decreased by ~20% and the cardiac output
improved by ~ 10% on average. Higher pump speeds (small
patient: >~5500rpm, large patient: >~6800rpm) led to the
elevation of the pulmonary pressure level to >25mmHg, which
is above safe physiological range [34]. Overall, the rpm values
for improving cardiac output while maintaining pressures
within safe physiological range was between 5000-6800 for the
large patient and 4400 to 5500 rpm for the small patient.
2) IVC assisted configuration
While the IVC support augmented the cardiac output and led
to a favourable decrease in the IVC pressure, the SVC pressure
increased to above 20mmHg even at the lowest pump speed
(4400rpm) for both patients. The IVC pressure was highly
sensitive to the pump speed, continually decreasing with
increasing pump speed.
IV. DISCUSSION
The Fontan procedure is currently the standard-of-care final
procedure for the palliation of single ventricle defects.
However, Fontan patients are predisposed to circulatory failure
as a result of the abnormal hemodynamics. This study aims to
evaluate the risks and benefits of the off-label use of a left VAD
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Fig. 6. Comparison of hemodynamic parameters during Full and IVC support at different rotor speeds. Simulation results of the (A)
large patient and (B) small patient. Cardiac output (CO), SVC pressure (Psvc), IVC pressure (Pivc), pulmonary pressure (Ppul).

during Full and IVC support in failing Fontan patients with
diastolic dysfunction. Through simulations, we showed that a
proper implementation of an arterial pump in the right
circulation could benefit the Fontan hemodynamics. We
constructed the failing Fontan model employing clinical data
available in the literature and found that the failing circulation
model to be in general agreement with previous reports [16],
[18], [35]. Our model sensitivity analysis showed the
association of the hemodynamic parameters (e.g. cardiac
output, IVC pressure, atrial pressure) with pulmonary vascular
resistance and ventricular diastolic dysfunction. The results of
this analysis suggested that the significant elevation of IVC
pressure in a failing circulation reported in previous clinical
studies [5], [28] is equally attributable to the high pulmonary
vascular resistance as well as elevated downstream pressure
related to ventricular compliance reduction. Furthermore,
deterioration of ventricular compliance had significant
implications on the atrial pressure, cardiac output, and central
venous pressure; thus, it is important to include ventricular
diastolic dysfunction in failing Fontan circulation models. The
sensitivity analysis indicated that changes in the ventricular
compliance and pulmonary vascular resistance had
considerable and minimal effects on atrial pressure,
respectively. This implies that elevated atrial pressure may be
an indication of ventricular diastolic dysfunction in failing
Fontan patients. The sensitivity analysis also showed that
ventricular diastolic dysfunction and elevated pulmonary
vascular resistance both decreased the cardiac output. Cardiac

output reduction and consequently further preload starvation
most likely will result in additional deterioration of the
ventricular diastolic function [23], [36] leading to a positive
feedback loop and eventually cardiac failure in failing Fontan
patients. Therefore, augmentation of the cardiac output is a
crucial factor for the survival of these patients.
The utilization of the right-side circulatory device to promote
the hemodynamics of a failing Fontan is appealing; however,
implanting the cavopulmonary device on the right circulation is
surgically complex. Implementation of the pump in a failing
Fontan requires additional invasive surgeries for taking down
the venae cavae for cannulation. From a surgical point of view,
the Full assist configuration is relatively more invasive because
of the additional steps necessary for detaching and
anastomosing both the SVC and IVC.
However, our simulations showed that IVC support had
limitations. While surgical implementation of IVC assist is
perhaps less complex, the model revealed that the pressure
generated by the pump even at the lowest speed was
excessively high (7mmHg at 1.66 L/min of flow) and resulted
in elevation of the SVC and pulmonary pressure to above
22mmHg and out of acceptable physiological ranges. Cerebral
venous thrombosis, a result of elevated central venous pressure,
is frequent after the Fontan operation (occurring in 21% of
patients) [37]–[39]. Precipitous rise of the SVC pressure due to
an IVC assist pump transmitted to the cerebral venous
circulation could further predispose the patient to thrombosis.
Shimazu et al. [15] reported that IVC assist is more suitable
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for Fontan cavopulmonary support. They modelled a similar
size example patient with weight=75 kg and BSA=1.9 m2. The
disparity between our conclusions is likely due to the
differences in the pump models employed and the cardiac
function prescribed in the physiology simulations. The pump
model that they employed was more compatible with the lowpressure environment. This pump, although not currently
commercially available, was capable of generating smaller
pressure boost at low flow rates (resulting in lower SVC
pressure). Additionally, their example patient had a normal
ventricular diastolic function and consequently higher IVC flow
and cardiac output. Nonetheless, their study also confirmed that
the elevation of the SVC pressure by the presence of the pump
is a major drawback of the IVC assist configuration.
Risk of venous collapse is another important concern with
the IVC assist configuration while using a left VAD. Rieme et
al. [13] observed the intermittent collapse of the IVC and
subsequent decrease in the IVC flow in animals after
implementing a HeartMate II in the IVC. Our simulation results
also implied the possibility of venous collapse at the inlet of the
pump due to the very low IVC pressure at high pump speeds.
On the other hand, for the fully assisted configuration the caval
pressure remained positive across all pump speeds we
examined; this result is consistent with the report by Gandolfo
et al. [17] where no venous collapse was observed after
implanting the Jarvik 2000 on the right circulation of four sheep
using the Full Support surgical configuration.
Although the risk for venous collapse was lower in Full
support, the simulations showed that over-filling of the Jarvik
pump at low pump speeds was a major shortcoming of this
configuration. In the large patient and for pump speeds
<5000rpm, the blood pump obstructed the flow and resulted in
a reduction of the cardiac output and undesirable increase of the
IVC and SVC pressure. However, in the small patient no pump
over-filling was observed due to the lower venous return flow
rates.
During Full support, we were able to identify a range of the
pump speed for each example patient that resulted in improved
hemodynamics. However, the optimal range was outside of the
off-the-shelf range of the Jarvik 2000 (i.e. 8000-12000rpm).
While maintaining all the pressure in the safe physiologic
range, the cardiac output increased by up to 30% at 5500rpm
and 6800rpm for the small and large patients, respectively. The
optimal pump speeds depended on the specific hemodynamics
of the failing patient and performance of the pump. Therefore,
subject-specific modelling is important for identifying suitable
pump speeds while investigating cavopulmonary assist.

the simulated hemodynamic outcomes. Another limitation of
the current study is that the LPN model is not able to resolve
vessel wall shear stress, which is known to impact endothelial
function and pulmonary vascular resistance in Fontan patients.
Finally, the numerical model is tuned based on clinical data
from adult patients [22], therefore the results should not be
expanded to pediatric patients.
V. CONCLUSION
The computational model we presented suggested that a
cavopulmonary VAD can benefit failing Fontan patients and
that IVC assisted configuration is associated with higher risks
compared to Full assist. The proper adjustment of a
cavopulmonary device depends on the device characteristics
and hemodynamic state of the patient; we therefore recommend
subject-specific modelling for identifying the pump speed range
that would benefit the patient. Future studies should focus on
designing a blood pump that has the performance requirements
for cavopulmonary application. We showed that, theoretically,
a modified left VAD (Jarvik 2000) implemented in the right
circulation can help failing Fontan patients. However, further
research is needed to examine the risks associated with the
modification of a left VAD to achieve lower pump speeds since
such modifications can affect the reliability and stability of the
device. Other methods for reducing the pressure generated by
the pump such as trimming of the rotor blades [17] can also be
further investigated in future studies.
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Erratum
Table I and equation (3) in the article “Risks and Benefits of Using a Commercially Available Ventricular
Assist Device for Failing Fontan Cavopulmonary Support: A Modeling Investigation”1 which was published
in the April 2019 issue of IEEE Transactions on Biomedical Engineering are corrected as follows. This does
not affect the study results. We sincerely apologize for the errors and any confusion they may have
caused.

ΔP = AQ3+BQ2+CQ+D

(3)

TABLE I
Coefficients for the Jarvik 2000 blood pump performance
characteristic model at different rotor speeds
Rotor
speed
(rpm)
4400
5500
7000
8500
9500

A

Coefficients
B
C

D

-0.72
-0.54
-0.85
-0.63
-0.75

-0.65
-0.97
3.67
2.94
5.62

20.55
30.83
56.91
79.86
107.2

-2.11
-1.18
-13.92
-14.23
-25.18
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